---
title: Hypertrophic Cardiomyopathy
subtitle: Echocardiography Case Conference
author: Anish S. Shah, MD, MS
institute: Division of Cardiology, University of Illinois at Chicago
format: 
  revealjs:
    scrollable: true
tbl-cap-location: bottom
fig-cap-location: bottom
---

```{r}
#| echo: false
#| label: setup
library(tidyverse)
library(ggsci)
```


## Overview

- Thought to be more rare, but now diagnosed more commonly
- Incidence of 1:200 to 1:500
- Range of phenotypic presentations, 15 mm to &ge; 30 mm LV wall thickness
- Clinical presentation along the spectrum of disease:
	- stable/benign
	- sudden death
	- obstructive physiology + heart failure
	- atrial fibrillation + stroke

::: aside
Maron et al. 2022, JACC
:::

## Clinical evaluation {.smaller}

a. Discuss: disease and its treatment strategies - genetic conditions necessitate both clinical and psychosocial considerations
a. HPI: focuses on syncope, prolonged palpitations, chest pain, family history of HCM or sudden death
a. Establish: LV morphology, stratify sudden death risk, classify if obstructive or not, family screening needs, and follow-up
a. Evaluate: TTE, ECG (12-lead + ambulatory), CMR, ESE, genetic testing
a. Follow-up: repeat imaging every 1-2 years (based on clinical setting)

---

![Clinical evaluation timeline](maron-2022-eval-schedule.png){#fig-timing}

::: aside
Maron et al. 2022, JACC
:::

## LVH associated with genetic variants

![Variant sub-type correlated with frequency of genetic mutations: sigmoid, reversse, neutral, apical (respectively)](binder-2006-lvh-variants.png){#fig-lvh-genes}

::: aside
Binder et al. 2006, Mayo Clin Proc
:::

## Diagnostic requirements {.bigger}

1. LV wall thickness &gt; 15 mm (13 to 14 mm with other risk features)
1. Unassociated with other cardiometabolic or systemic disease
1. Sarcomere mutation or other genetic variant

::: aside
Gersh, BJ, et al. 2011, JACC
:::

## Non-mandatory findings

- Asymmetrical septal hypertrophy
- Systolic anterior motion
- Dynamic LVOT obstruction

## Where is the LVH?

```{r}
#| label: fig-lvh-location
#| fig-cap: Frequency of LVH location
df <-
	tribble(
		~Location, ~Frequency,
		"Anterior septum", 0.25,
		"Anterior and inferior", 0.31,
		"Septum and anterolateral", 0.17,
		"Septum and free wall", 0.17,
		"Lateral", 0.01,
		"Anterior septum and anterolateral", 0.07,
		"Apex", 0.02
	)

ggplot(df, aes(x = "", y = Frequency, fill = Location)) +
	geom_bar(width = 1, stat = "identity") +
	scale_fill_jama() +
	scale_y_continuous(labels = scales::percent) + 
	theme_minimal() +
	theme(
		axis.title = element_blank()
	)  + 
	coord_polar("y", start = 0) 
```

::: aside
Klues HG, 1995, JACC
:::

## Classify LVH morphology

::: {#fig-lvh-variants layout-ncol=3}

![Sigmoid](ommen-2016-sigmoid-cartoon.png){#fig-lvh-sigmoid}

![Reverse](ommen-2016-reverse-cartoon.png){#fig-lvh-reverse}

![Apical](ommen-2016-apical-cartoon.png){#fig-lvh-apical}

Location of hypertrophy defines the morphology. No matter where, __any region &gt; 30 mm increases risk of SCD, as well as apical pouch__. 
:::

::: aside
Ommen et al. 2016, JASE
:::

## SAM

![The _Venturi effect_. LV ejection &rarr; obstruction &rarr; MR.](silbinger-2016-sam-cartoon.png){#fig-sam}

::: aside
Silbinger 2016, JASE
:::

## Gradients {.smaller}

We can compare LV systolic pressure with systemic systolic pressure to estimate obstructive gradients:

$$ LV\ Systolic\ Pressure = 4 \times (MR\ velocity)^{2} + LA\ Pressure$$

- Peak LVOT gradient of &ge; 50 mmHg at rest or with provocation or exercise indicates obstruction 
- Differentiate SAM-mediated LVOT obstruction from mid-ventricular obstruction (MVO; “dagger” shaped) 

_MR signal is both higher and longer, thus may contaminate LVOT signal_

---

![Gradient types based on MVO versus SAM](ommen-2016-gradient-profiles.png){#fig-gradient-profiles}

::: aside
Ommen et al. 2016, JASE
:::

## Pre-operative strategies

Surgical septal myectomy and alcohol septal ablation should have TEE support. Measure:

a. IVS maximum thickness
a. anterior leaflet length
a. apical extent of the septal "bulge"
a. distance between aortic annulus to mitral-septal continuity

_Follow-up TTE in 3-6 months._

# End